Introduction {#s1}
============

Zika virus (ZIKV) is a mosquito-borne flavivirus that is closely related to dengue (DENV) and yellow fever viruses (YFV). There are three ZIKV genotypes: one from Asia, which has caused the recent pandemic in the Americas, and two from Africa (East and West African) ([@bib48]). ZIKV infection is characterized by fever, arthralgia and conjunctivitis ([@bib32]) and was considered an exceedingly rare human infection since only 14 cases were reported prior to 2007 ([@bib28]). In 2007, the first ZIKV outbreak caused by an Asian lineage was reported in Micronesia, followed by epidemics in French Polynesia in 2013 and the recent pandemic (2015--2016) in the Americas ([@bib70]; [@bib3]). During this period, it has been estimated that 1.5 million cases occurred in Brazil and more than 25,000 cases in Colombia ([@bib31]; [@bib64]). As of January 2018, the virus was widely distributed in 50 countries in the Americas ([@bib58]). The public health concern about Zika has been primarily driven by its maternal-fetal ([@bib10]; [@bib74]; [@bib26]) and sexual modes of transmission ([@bib22]; [@bib20]; [@bib40]) as well as its association with congenital abnormalities, especially microcephaly, and Guillain-Barré syndrome in adults ([@bib46]; [@bib52]; [@bib55]; [@bib11]). These unique aspects set ZIKV apart from other flavivirus infections and have spurred efforts to understand ZIKV host-pathogen interactions.

The ZIKV life-cycle starts with virus attachment and receptor-mediated endocytosis ([@bib35]; [@bib54]). Upon endosome acidification, the viral envelope fuses with the endosomal membrane, releasing the nucleocapsid into the cytoplasm for uncoating and initial viral translation at the cytosolic surface of the endoplasmic reticulum (ER). Translation produces a single polyprotein that is cleaved co- and post-translationally by cellular and viral proteases into 10 mature proteins: three structural proteins forming the virion (capsid, C; pre-membrane, prM; and envelope, E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) required for viral replication and inhibition of host defense mechanisms ([@bib12]; [@bib7]). Replication of ZIKV RNA and assembly of viral particles occur in close association with rearranged ER membranes ([@bib62]). Assembled virions are transported through the secretory pathway, where the furin protease cleaves prM into and M, resulting in mature virions that are secreted into the extracellular space ([@bib38]).

The flaviviral genome contains 5′ and 3′ untranslated regions (UTR) that are essential for genome cyclization and initiation of RNA synthesis ([@bib29]; [@bib4]). The ZIKV 3′ UTR is highly structured and consists of four domains: xrRNA1, xrRNA2, the dumbbell (DB) and the 3′ SL ([@bib77]). The ZIKV 3′ UTR contains confirmed and predicted pseudoknot interactions located in xrRNA1 and xrRNA2, respectively. These pseudoknots are important for stalling of the cellular 5′ to 3′ exonuclease, XRN1, and accumulation of at least two sfRNA species (sfRNA1 and sfRNA2) ([@bib2]). The sfRNA of a few different flaviviruses has been described to exert pro-viral functions, possibly through acting as a 'sponge' for antiviral host proteins ([@bib33]). The DENV sfRNA has been shown to interact with stress granule associated proteins G3BP1, G3BP2 and CAPRIN1 and the ubiquitin ligase TRIM25 to dampen innate immune responses ([@bib8]; [@bib51]). Similarly, Moon et al reported that DENV-2 and KUNV sfRNAs inhibited XRN1 activity, leading to accumulation of uncapped transcripts in infected cells and disruption of mRNA homeostasis that could potentially deregulate antiviral responses ([@bib56]). Regarding ZIKV, Musashi-1 (MSI1) was reported to be required for efficient infection and interact with viral genomes; additionally, ZIKV infection disrupted the activity of MSI1 (33). However, whether or not ZIKV sfRNA interacts with MSI1 and modulates its activity is unclear.

In this work, we identified the Fragile X Mental Retardation Protein (FMRP) as a host factor that binds to the ZIKV sfRNA and to viral genomes. Functional assays indicated that FMRP represses ZIKV infection by inhibiting viral translation. Analysis of an attenuated ZIKV vaccine candidate (Δ10 ZIKV) that is defective for sfRNA production suggests that sfRNA enhances ZIKV infection partly through antagonizing FMRP activity. Additionally, we observed that ZIKV infection blocks the canonical activity of FMRP and increases the expression of FMRP target genes. Finally, we present evidence implicating deregulation of FMRP activity in a mouse model of ZIKV infection, suggesting that ZIKV pathogenesis may involve virus-mediated FMRP inhibition.

Results {#s2}
=======

FMRP interacts with the ZIKV 3′ UTR in cell extracts, infected cells and infected mouse testes {#s2-1}
----------------------------------------------------------------------------------------------

Before this work, there was no knowledge of host proteins that bind and are modulated by ZIKV sfRNA. We previously used RNA affinity chromatography coupled with quantitative mass spectrometry (RAC-MS) to identify proteins that interact with DENV-2 sfRNA ([@bib8]; [@bib51]). Here, we used a similar approach with lysates from JEG3 (choriocarcinoma) cells, which are permissive for ZIKV infection, to identify host proteins that interact with full-length ZIKV 3′ UTRs of the pandemic Asian lineage strain PRVABC59 and the African strain MR766. This analysis revealed 27 proteins that preferentially interacted with the ZIKV RNAs compared to an RNA derived from the coding sequence of DENV ([Table 1](#table1){ref-type="table"}-source data 1). We also analyzed a second negative control RNA derived from vector backbone sequence and obtained similar results (data not shown). We did not detect major differences in the protein-binding profiles of PRVABC59 and MR766 ZIKV sequences. Eight proteins that were identified by ≥2 unique peptides and were ≥2 times as abundant in both the ZIKV sequences relative to the control RNA were considered as high-confidence ZIKV 3′ UTR binding proteins ([Table 1](#table1){ref-type="table"}). The proteins showing highest preferential binding to ZIKV sfRNAs were FMRP and its two paralogs, Fragile X Related proteins 1 and 2 (FXR1 and FXR2) for both ZIKV 3′ UTRs.

10.7554/eLife.39023.003

###### List of ZIKV 3′ UTR binding proteins identified by label-free mass spectrometry.

10.7554/eLife.39023.004Table 1---﻿source data 1.

                                          Normalized abundance^§^   Ratio vs NS2A^\#^                      
  -------------------------- ---- ------- ------------------------- ------------------- ----------- ------ ----
   sp\|P51116\|FXR2_HUMAN    2    129.6   1.8E + 04                 6.1E + 05           8.2E + 05   34.3   46
   sp\|P51114\|FXR1_HUMAN    12   897.8   6.2E + 05                 8.2E + 06           9.9E + 06   13.4   16
   sp\|Q06787\|FMR1_HUMAN    6    361.7   1.1E + 05                 1.4E + 06           1.7E + 06   12.3   15
   sp\|P26196\|DDX6_HUMAN    9    723.9   4.7E + 05                 2.0E + 06           3.9E + 06   4.2    8
   sp\|Q9Y520\|PRC2C_HUMAN   4    218.0   3.8E + 04                 1.3E + 05           1.8E + 05   3.3    5
   sp\|P15927\|RFA2_HUMAN    2    165.8   3.5E + 04                 1.6E + 05           1.3E + 05   4.7    4
   sp\|Q8N0V3\|RBFA_HUMAN    2    136.3   7.3E + 04                 1.6E + 05           2.2E + 05   2.2    3
   sp\|P06748\|NPM_HUMAN     5    623.9   5.5E + 06                 1.1E + 07           1.6E + 07   2.0    3

\*Unique identifier number of the protein.

†Number of peptide sequences uniquely identified for each protein.

‡Confidence score (−10logP) reflects how well the MS/MS spectrum matches the peptides for all observed mass spectra that correspond to sequences within the protein. A higher score indicates a more confident match.

§Protein abundances were calculated by measuring the area under the curve of the corresponding peaks in the ion chromatogram.

\#Protein abundances of RBPs interacting with PRVABC59 and MR766 ZIKV 3′ UTRs were compared with NS2A control RNA to calculate ratio of enrichment (PRVABC59 3′ UTR/NS2A and MR766 3′ UTR/NS2A). Proteins enriched \>2 fold and with unique peptides ≥ 2 were considered to be high-confidence ZIKV 3**′** UTR interacting proteins.

In order to map the region(s) of the ZIKV 3′ UTR that mediate binding of FXR proteins, we performed an RNA affinity chromatography experiment using HeLa lysate and fragments of the ZIKV- PRVABC59 3′ UTR, and probed for proteins by western blotting (WB). As expected, the complete 3′ UTR interacted with FMRP, FXR1 and FXR2 ([Figure 1](#fig1){ref-type="fig"}, lane 1). Deletion of xrRNA1 dramatically reduced interaction with all three proteins (lane 2) and deletion of xrRNA1 and 2 eliminated detectable binding. Additionally, xrRNA1 alone was sufficient to bind FMRP, FXR1 and FXR2 (lane 4). These data indicate that xrRNA1 is necessary and sufficient for efficient binding to these proteins. We also probed for DDX6, G3BP1 and PTB. DDX6 interacted specifically with the ZIKV dumbbell region in contrast to FMRP. Interestingly, PTB and G3BP1, which were previously reported to interact with the DENV 3′ UTR ([@bib8]; [@bib21]), did not strongly interact with ZIKV 3′ UTR ([Figure 1](#fig1){ref-type="fig"}).

![xrRNA1 is required and sufficient for FMRP binding to the ZIKV 3′ UTR.\
(**A**) Schematic illustrating the secondary structures present in the ZIKV 3′ UTR and RNAs used for affinity chromatography. Deletion mutant RNA constructs fused to a tobramycin aptamer at the 5′ end are shown. DENV NS2A coding sequence was used as a negative control RNA. (**B**) Purified RNAs bound to tobramycin-sepharose beads were incubated with HeLa cell lysate and unbound proteins were washed away prior to elution for western blotting for DDX6, FMRP, FXR1, FXR2, G3BP1 and PTB.](elife-39023-fig1){#fig1}

We chose to focus on FMRP due to its strong association with ZIKV RNA in binding experiments ([Figure 1B](#fig1){ref-type="fig"}), well-established association with human neurodevelopmental disease, and high level of expression in tissues relevant to ZIKV, such as brain and reproductive tract ([@bib24]). To validate the interaction of FMRP with ZIKV 3′ UTR in the context of ZIKV infection, we performed RNA immunoprecipitation (RIP) with anti-FMRP antibody or isotype control and detected ZIKV RNAs using northern blot (NB) ([Figure 2A](#fig2){ref-type="fig"}). HeLa cells were infected with Dakar 41525 (ZIKV-Dakar), Cambodia FSS13025 (ZIKV-Cambodia) or PRVABC59 (ZIKV-Puerto Rico) strains, cell lysates were collected and FMRP was immunoprecipitated. Total RNA interacting with FMRP was isolated and the presence of ZIKV RNAs was detected by NB using a DNA probe that hybridizes to the ZIKV 3′ UTR. Both ZIKV sfRNA and viral genome co-precipitated with anti-FMRP but not control IgG ([Figure 2A](#fig2){ref-type="fig"}) for all three virus strains. Interestingly, quantification of sfRNA and genomic RNA signals indicated that FMRP preferentially interacts with the ZIKV sfRNA ([Figure 2B](#fig2){ref-type="fig"}). We additionally performed RIP with anti-PTB and isotype control antibodies and showed that viral genomes and sfRNA minimally co-precipitated with PTB and enrichment was much weaker than that for FMRP RIP ([Figure 2C](#fig2){ref-type="fig"}). We also analyzed the integrity of unbound viral RNAs present in supernatants after RIP. This analysis revealed that viral RNAs did not degrade during the RIP procedure ([Figure 2C](#fig2){ref-type="fig"}).We determined whether or not the interaction of FMRP with ZIKV RNA occurs in testes of infected mice. We selected testes for analysis because this tissue exhibits relatively high viral load in the A129 mouse model (IFNAR1 knockout) of ZIKV infection ([@bib25]; [@bib61]). FMRP was subjected to IP from testes lysates of mice infected with ZIKV-Cambodia for 6 days and RT-qPCR was used to measure co-precipitating viral RNA using qPCR assays targeting the viral genome exclusively or both the genome and sfRNA ([Figure 2D](#fig2){ref-type="fig"}). We observed enrichment of viral genomes by \~2 fold for FMRP IP compared to the negative control. Importantly, the enrichment was nearly twice as robust when using a qPCR assay that detects both genomes and the sfRNA. These results validate the interaction of FMRP with ZIKV RNA in vivo and, as observed in infected cultured cells, indicate preferential binding of FMRP to the ZIKV sfRNA.

![FMRP interacts with ZIKV RNA in infected cells.\
(**A**) RNA immunoprecipitation (RIP) was performed using either control IgG or anti-FMRP antibodies. HeLa cells were infected with the indicated virus at MOI of 3 and harvested 48 hr post-infection. Viral genome (gRNA) and the subgenomic flaviviral RNA (sfRNA) were detected by Northern blot (NB) using a DNA probe that hybridizes to the ZIKV 3′ UTR. Western blotting (WB) shows the specificity of FMRP IP. (**B**) Bar graph showing the preferential binding of FMRP to ZIKV sfRNA. Densitometry analysis of NB assays was performed to determine relative levels of co-precipitating gRNA and sfRNA compared to input signals. Enrichment of sfRNA was normalized to the gRNA enrichment. Data represents the mean ± SEM of three independent experiments for ZIKV-Dakar and ZIKV-Cambodia (\*p\<0.05). One experiment was performed for ZIKV-Puerto Rico. (**C**) RNA IP from HeLa cells infected with ZIKV-Dakar using anti-PTB, anti-FMRP and isotype control antibodies. (**D**) FMRP interacts with ZIKV RNA in infected mouse testes. Testes from ZIKV-infected mice were lysed and used for FMRP-RIP. RT-qPCR assays were used targeting the ZIKV ORF, to measure viral genomes exclusively, and the 3′ UTR, to measure both genomes and sfRNA. Bar graph represents the enrichment of viral RNAs in FMRP-pulldown normalized to the control IgG. Data indicates the mean ± range of two biological replicates. The WB shows IP of FMRP. \
10.7554/eLife.39023.007Figure 2---source data 1.](elife-39023-fig2){#fig2}

FMRP represses ZIKV infection by blocking viral RNA translation {#s2-2}
---------------------------------------------------------------

Given the binding of FMRP to ZIKV sfRNA, we hypothesized that this protein would play an antiviral role for ZIKV. To analyze the functional relevance of FMRP in ZIKV infection, we infected HeLa cells in which FMRP was knocked down (KD) with individual siRNAs or a pool of four different siRNAs ([Figure 3A](#fig3){ref-type="fig"}). Forty-eight hours post-infection with ZIKV-Dakar at low MOI (0.01), we measured viral titers using plaque assay and rate of infection by flow cytometry. Both viral titers and rate of infection were increased by 2- to 5-fold due to FMRP KD ([Figure 3B and C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). The pooled siRNAs effectively reduced FMRP levels and this correlated with large increases in ZIKV infection. The antiviral effect of FMRP was corroborated by immunofluorescence (IF) of infected cells to detect viral antigen and analysis by high-content imaging ([Figure 3D](#fig3){ref-type="fig"}). Moreover, we observed that FMRP KD enhanced infection with Asian strains (ZIKV-Cambodia and ZIKV-Puerto Rico) to different extents, but did not impact infection by DENV-2 ([Figure 3---figure supplement 1B and C](#fig3s1){ref-type="fig"}). We additionally tested the effect of FXR1 and FXR2 knockdown on ZIKV infection. We observed a slight increase in virus infection rate for FXR1 depletion while FXR2 knockdown significantly reduced infection ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Together, these observations suggest that FMRP acts as a specific restriction factor for multiple ZIKV strains.

![Depletion of FMRP increases ZIKV infection.\
HeLa cells were transfected with control siRNA (siControl) and individual or a pool of four different siRNAs targeting FMR1 (siFMR1). Cells were infected with ZIKV-Dakar at MOI 0.01 for 48 hr. (**A**) Representative WB of FMRP knockdown efficiency. Relative FMRP expression is indicated below. (**B**) Viral titers in supernatants were measured by plaque assay and are plotted as PFU/ml. (**C**) Infection rates were measured by immunofluorescence against viral envelope (**E**) protein using flow cytometry (representative scatter plots are shown in [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) or (**D**) high-content imaging. Data represent the mean ±SEM of two independent experiments. (**E**) HeLa cells were transfected with siControl or siFMR1 (pool) and infected with ZIKV-Cambodia (MOI 0.01), ZIKV-Puerto Rico (MOI 0.01) or DENV-2-NGC (MOI 0.03) 48 hr later. At 48 hr post-infection, supernatants were collected and analyzed for viral titers. Graphs represent the mean ±SD of PFU/mL of one of three independent experiments for ZIKV-Cambodia and ZIKV-Puerto Rico. For DENV-NGC, three biological replicates are plotted (\*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.001). NI, non-infected cells.\
10.7554/eLife.39023.012Figure 3---source data 1.](elife-39023-fig3){#fig3}

We also tested the effect of FMRP KD under experimental conditions that interrogate virus infection at higher MOI and shorter infection time, and observed that FMRP KD increased infection rate from \~50% to\~80% ([Figure 3---figure supplement 3A and B](#fig3s3){ref-type="fig"}). Analysis of fluorescence intensity (FI) histograms ([Figure 3---figure supplement 3C](#fig3s3){ref-type="fig"}) revealed the presence of two distinct populations of infected cells: one of low FI and a second of high FI for expression of viral envelope (E) protein. Cells transfected with non-targeting siRNA (blue histogram) were predominantly in the low-infected cell population. In contrast, cells transfected with siRNAs targeting FMRP (red histogram) were mostly in the highly-infected population. We calculated FI mode values, indicating the maximum FI peak for each condition and found that FMRP knockdown led to a \~ 10 fold increase, indicating elevated levels of E protein expression ([Figure 3---figure supplement 3D](#fig3s3){ref-type="fig"}). WB analysis revealed increased NS4B and NS2B protein levels in FMRP KD cells infected with ZIKV at MOIs of 1 and 5 ([Figure 3---figure supplement 3E and F](#fig3s3){ref-type="fig"}). Together, these data indicate that during a single ZIKV replication cycle, the absence of FMRP significantly increases both the rate of infection and the level of viral protein accumulation per cell.

Because FMRP is known to be a repressor of cellular mRNA translation ([@bib75]; [@bib47]), we hypothesized that translation of ZIKV is inhibited by FMRP early after infection. To test this hypothesis, we used an infectious ZIKV that expresses NanoLuc luciferase and analyzed early accumulation of NanoLuc in control and FMRP KD cells. Treatment with the translation elongation inhibitor cycloheximide (CHX) was used to control for background signal present in the virus stock. The Nanoluc signal observed in control cells was well above that detected in the CHX-treated control at 3.5 hr post infection (hpi) indicating measurable viral protein synthesis at this early time point. Importantly, we observed a 4-fold increase in NanoLuc signal in FMRP depleted cells (siFMR1) compared to control siRNA transfected cells, suggesting that FMRP depletion results in increased of ZIKV translation ([Figure 4A and B](#fig4){ref-type="fig"}). Similar effects were observed in the presence of NITD008, a potent inhibitor of the flaviviral NS5 RNA-dependent RNA polymerase ([@bib23]; [@bib73]), ruling out a possible contribution of RNA replication to the increased luciferase signal in FMRP KD cells ([Figure 4A and B](#fig4){ref-type="fig"}). Consistent with this, we did not observe significant differences in viral RNA accumulation between control and FMRP KD cells in the absence or presence of NITD008 ([Figure 4C](#fig4){ref-type="fig"}). Finally, we calculated a 3.5-fold increase of ZIKV translation efficiency (NanoLuc levels normalized to ZIKV RNA) in FMRP KD cells compared to the negative control in both the absence and presence of NITD008 ([Figure 4D](#fig4){ref-type="fig"}). Together, these results strongly suggest that FMRP inhibits ZIKV infection by reducing viral translation.

![FMRP inhibits ZIKV translation early after infection.\
(**A**) An infectious ZIKV reporter virus expressing NanoLuc luciferase was used to evaluate ZIKV translation. HeLa cells were transfected with control siRNA (siControl) or the siRNA pool targeting the FMR1 gene (siFMR1). Two hours before infection, cells were pretreated with DMSO (-NITD008) or NITD008 at 20 μM. Accumulation of Nanoluc was evaluated at 3.5 hr post-infection. Cycloheximide (CHX) treatment was used to control for background signal present in the virus stock. (**B**) The graph shows luminescence signals with background (CHX control) subtracted and normalized to the siControl condition. (**C**) In parallel, viral RNA was measured by RT-qPCR, calibrated with GADPH mRNA expression and normalized to siControl. (**D**) Translation efficiency was calculated by normalizing the luminescence signals to ZIKV RNA levels. Data represent mean ±SEM of one representative experiment for A, three independent experiments for B and two independent experiments for C and D. (\*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.001). .\
10.7554/eLife.39023.014Figure 4---source data 1.](elife-39023-fig4){#fig4}

ZIKV sfRNA antagonizes FMRP function {#s2-3}
------------------------------------

Because FMRP binds preferentially to ZIKV sfRNA, we tested the hypothesis that sfRNA, which accumulates to high levels during the course of infection ([Figure 2A](#fig2){ref-type="fig"}), is capable of attenuating FMRP-mediated anti-ZIKV activity. For this purpose, we analyzed a ZIKV mutant (Δ10 ZIKV) that contains a 10-nt deletion within the 3′ UTR DB structure and is highly attenuated in mice and non-human primates ([@bib66]; [@bib67]). We first asked whether Δ10 ZIKV is deficient in sfRNA production. Analysis of viral RNA from infected HeLa cells demonstrated that Δ10 ZIKV has a defect in sfRNA accumulation. An sfRNA/gRNA ratio of 2.7 was observed in WT ZIKV infected cells but the ratio was only 0.6 in Δ10 ZIKV infected cells. These results suggest that Δ10 ZIKV is attenuated, as least in part, through loss of sfRNA accumulation caused by the 10-nt deletion ([Figure 5A and B](#fig5){ref-type="fig"}).

![ZIKV sfRNA antagonizes FMRP's antiviral function.\
(**A**) HeLa cells were infected at MOI of 3 with WT ZIKV or ∆10 ZIKV. 24 hr post-infection, cell-associated RNA was harvested and levels of gRNA and sfRNA were analyzed by NB. (**B**) sfRNA/gRNA ratios for WT and ∆10 ZIKV were calculated by densitometry analysis of two independent experiments. (**C--G**) HeLa cells were transfected with control siRNA (siControl) and pooled FMR1 siRNAs for 48 hr. Cells were then infected with WT and ∆10 ZIKV at MOI of 0.2 and 24 hr later collected and analyzed for infection rate by flow cytometry (**C and D**). Representative scatter plots are shown in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}. In parallel, viral NS4B and NS2B proteins were analyzed by WB along with FMRP and Actin loading control (**E**). The quantitative expression levels of NS2B (**F**) and NS4B (**G**) are shown. Data represents the mean ±SEM of one representative experiment for C, four independent experiments for D and two independent experiments for F and G. (\*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.001. a = *p* \< 0.01 compared to siControl cells infected with WT ZIKV). .\
10.7554/eLife.39023.017Figure 5---source data 1.](elife-39023-fig5){#fig5}

Next, we asked whether the WT and mutant viruses exhibit differential sensitivity to FMRP depletion. We observed that Δ10 ZIKV infection rate in HeLa cells is reduced compared to WT ZIKV under negative control conditions (\~11% vs\~25% infected cells) and, importantly, FMRP KD disproportionately enhanced Δ10 ZIKV infection rate ([Figure 5C](#fig5){ref-type="fig"}): whereas WT virus was enhanced by approximately 3-fold, the infection rate for Δ10 ZIKV rose by nearly 5-fold ([Figure 5D](#fig5){ref-type="fig"}). Representative scatter plots depicting the infected cell populations are shown in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}. Additionally, similar effects were observed on levels of cell-associated ZIKV NS2B and NS4B proteins ([Figure 5E](#fig5){ref-type="fig"} to G). Together, these results suggest that sfRNA antagonizes FMRP and thus enhances ZIKV infection.

Given the key role of FMRP in neurodevelopment, its mechanism of action has been extensively studied and several cellular mRNAs are known targets for translational repression by FMRP ([@bib75]; [@bib6]; [@bib45]). We examined expression levels of ten reported targets in control and FMRP-depleted HeLa cells: *ARC RHOA, SOD1, RAC1, PNPLA6, KDM5C, TSC2, FXR2, TLN1* and *BRD4*. Protein levels of FXR2, TLN1 and BRD4 increased after transfection of siRNA targeting FMRP ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) suggesting that the mRNAs encoding these proteins are genuine FMRP targets in HeLa cells. The remaining proteins were either undetectable (ARC) or were unaffected (RAC1, Rho A, PNPLA6, KDM5C, TSC2, SOD1) which suggests that FMRP may have cell-type specific effects ([@bib6]; [@bib19]).

To probe for antagonistic effects of ZIKV sfRNA on FMRP activity, the expression of FMRP targets was evaluated in the context of infection. First, we analyzed expression levels of FXR2 by WB in HeLa cells infected with WT ZIKV and Δ10 ZIKV. In order to achieve similar infection rates for the two viruses, cells were infected at MOI of 3 for WT ZIKV and MOI of 4.5 for the mutant virus. Interestingly, these experiments revealed a 2.7-fold-increase of FXR2 protein levels in cells infected with WT ZIKV ([Figure 6A and B](#fig6){ref-type="fig"}). Although Δ10 ZIKV infection also increased the mean level of FXR2, this effect was not statistically significant (p=0.277) compared to uninfected cells. In parallel, we measured the expression of FXR2 by flow cytometry in ZIKV-infected cells using a double staining protocol. [Figure 6C](#fig6){ref-type="fig"} shows the distributions of the cells based on infection with either WT ZIKV or Δ10 ZIKV, indicating similar levels of infection for both viruses (\~86% for WT and \~90% for Δ10 ZIKV). FXR2 mean fluorescence intensity (MFI) was enhanced by WT virus and, to a lesser extent, by the Δ10 ZIKV mutant. Quantitatively, there was a two-fold increase of FXR2 MFI in WT ZIKV infected cells and a 1.5-fold increase for Δ10 ZIKV compared to uninfected cells ([Figure 6D](#fig6){ref-type="fig"}). We also conducted IF microscopy analysis and observed FXR2 accumulation specifically in ZIKV-infected cells ([Figure 6E](#fig6){ref-type="fig"}). Interestingly, infection of cells by Δ10 ZIKV caused FXR2 to redistribute into discrete cytoplasmic puncta which was also evident at reduced frequency in WT ZIKV-infected cells. FXR2 has been previously reported to concentrate in stress granules ([@bib34]), suggesting that infection with the attenuated virus may induce formation of stress granules more efficiently than WT ZIKV. In addition to FXR2, we also observed elevated expression of TLN1 by WB in cells infected with WT ZIKV compared with uninfected and Δ10 ZIKV infected cells ([Figure 6---figure supplement 2A and B](#fig6s2){ref-type="fig"}).

![ZIKV infection increases expression of FXR2.\
HeLa cells were infected with WT (MOI of 3) or ∆10 ZIKV (MOI of 4.5) or left non-infected (NI). At 24 hr post-infection, cells were harvested and analyzed for FXR2 expression. (**A**) WB showing expression of FXR2, GAPDH and ZIKV NS4B. (**B**) Normalized expression levels of FXR2 from panel A are shown. (**C**) Flow cytometry for FXR2 and ZIKV E protein. E protein was stained using the 4G2 antibody and Alexa fluor 488-labeled secondary antibody. FXR2 protein was stained with anti-FXR2 and Alexa fluor 647-labeled secondary antibody. Scatter plots indicate the distribution of ZIKV positive cells in the NI cells (black, top left panel), WT ZIKV (blue, top right panel) and ∆10 ZIKV (red, bottom left panel) infected cells. Histograms (bottom right panel) indicate FXR2 expression as Alexa fluor 647 mean fluorescence intensity (MFI). (**D**) Graph shows the FXR2 MFI. Data is presented as the mean ±SEM of one of three independent experiments (\*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.001). (**E**) Representative immunofluorescence images from two independent experiments indicate the accumulation of FXR2 (red) in cells infected with WT and ∆10 ZIKV (green). Nuclei were counterstained with Hoechst 33342. White scale bar = 20 µm. \
10.7554/eLife.39023.021Figure 6---source data 1.](elife-39023-fig6){#fig6}

We further assayed the expression of BRD4 in ZIKV-infected cells. Although the anti-BRD4 antibody used recognizes the largest known BRD4 isoform, we observed a second and faster migrating band of \~175 kDa that appeared only in ZIKV-infected cells ([Figure 6---figure supplement 2C](#fig6s2){ref-type="fig"}). Since there are no annotated isoforms of this predicted mass, the data suggest that BRD4 is cleaved during ZIKV infection. We analyzed the sum of signals for both 204 kDa and 175 kDa BRD4 species and observed a 1.6-fold increase of BRD4 expression only in WT ZIKV infected cells ([Figure 6---figure supplement 2D](#fig6s2){ref-type="fig"}).

ZIKV sfRNA interferes with FMRP-mediated translational repression in uninfected cells {#s2-4}
-------------------------------------------------------------------------------------

To further test the role of sfRNA we asked whether or not this noncoding RNA could modulate expression of FMRP targets in the absence of infection. Electroporation was used to transfect full-length, in vitro synthesized sfRNA or a deletion mutant lacking xrRNA1 and xrRNA2 (DBSLIII). We electroporated RNAs with either 5′ triphosphate or monophosphate into HeLa cells and evaluated RNA integrity and abundance side-by-side with sfRNA from infected cells. We detected three distinct sfRNA species in infected cells that have been previously reported for ZIKV: sfRNA1, sfRNA2 and sfRNA3 ([Figure 7A and B](#fig7){ref-type="fig"}) ([@bib30]). Electroporated RNAs were partially degraded although some intact sfRNA remained even at 48 hr post-electroporation. In parallel, we analyzed the expression of the FMRP targets FXR2 and BRD4 by flow cytometry ([Figure 7B](#fig7){ref-type="fig"} to F). Compared to the DBSLIII RNA, electroporation of intact sfRNA resulted in modest, but highly significant, increases in both FXR2 and BRD4 levels. These results suggest expression of ZIKV sfRNA is sufficient to interfere with FMRP. We next asked whether ZIKV infection alters the expression of FMRP targets in mice ([Figure 8](#fig8){ref-type="fig"}). Male A129 mice were infected with WT (n = 4) or Δ10 ZIKV (n = 4) using 1 × 10^5^ FFU. At 6 days post-infection, protein expression levels of FXR2 and PNPLA6 \[a validated FMRP target ([@bib6])\] were measured in testes. In WT ZIKV-infected mice, we observed statistically significant increases in expression of both FXR2 (1.6-fold) and PNPLA6 (2.5-fold) compared to uninfected mice ([Figure 8A,C and D](#fig8){ref-type="fig"}). For Δ10 ZIKV-infected mice, expression levels of FXR2 and PNPLA6 were elevated to lesser extents, but these effects were not statistically significant. Measurements of viral genomes indicated a higher burden of infection for the WT virus than Δ10 ZIKV ([Figure 8B](#fig8){ref-type="fig"}) which may contribute to the differential effects on FXR2 and PNPLA6 levels. Nevertheless, these data taken together with observations made in cultured cells ([Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"} and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), implicate the ZIKV sfRNA as an antagonist of FMRP function.

![ZIKV sfRNA increases expression of FXR2 and BRD4 in the absence of infection.\
Electroporated 5′ triphosphate (**A**) or monophosphate (**D**) RNAs were analyzed by northern blot, 48 hr after electroporation. Total RNA from cells infected with ZIKV-Puerto Rico was analyzed to visualize the presence of sfRNA1, sfRNA2 and sfRNA3. The expression levels of FXR2 and BRD4 were evaluated by flow cytometry in cells electroporated with 5′ triphosphate (**B,C**) or monophosphate (**E,F**) RNAs. Mean fluorescence intensities (MFI) in presence of the mutant control DBSLIII (blue) and sfRNA (red) are shown. Plots in C and F represent the mean ±SD of four and two independent experiments, respectively. (\*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.001). MFI intensities were normalized to the mutant control. .\
10.7554/eLife.39023.023Figure 7---source data 1.](elife-39023-fig7){#fig7}

![ZIKV infection increases the expression of FMRP targets in infected mouse testes.\
A129 mice were non-infected (NI; N = 3) or infected with WT (N = 4) or ∆10 ZIKV (N = 4) with 1 × 10^5^ FFU. At 6 days post-infection, mice were euthanized, and testes were removed for lysis. (**A**) Protein expression levels of FXR2 and PNPLA6 were analyzed by WB. No FXR2 was detected in mouse \#2 infected with ∆10 ZIKV and we therefore eliminated this sample from the analysis. (**B**) A fraction of testes lysates was processed for RNA isolation and levels of viral genomes were measured by RT-qPCR using a pair of primers that amplify a region of the ZIKV ORF. GAPDH was used as loading control for WB assays and calibrator gene for RT-qPCR. Relative protein expression levels of FXR2 (**C**) and PNPLA6 (**D**) were measured by densitometry analysis, adjusted to loading control and normalized to non-infected mouse (NI). Error bars represent the mean ±SEM of three mice for non-infected condition (NI), four mice for WT ZIKV and three mice for ∆10 ZIKV. \*p\<0.05. N.D, non-detected. .\
10.7554/eLife.39023.025Figure 8---source data 1.](elife-39023-fig8){#fig8}

Discussion {#s3}
==========

Here, we report functional interactions between ZIKV and FMRP, an important regulatory factor in neurodevelopment ([@bib37]; [@bib43]). FMRP interacted with ZIKV RNA, with particular affinity for the sfRNA, in both infected cultured cells and mouse testes. FMRP interaction with the viral genomic RNA presumably limits infection through inhibiting early synthesis of viral proteins. Importantly, accumulation of ZIKV sfRNA suppressed the anti-viral activity of FMRP and, consequently, resulted in de-repression of endogenous FMRP target mRNAs. Together, our observations have important implications for ZIKV infection and pathogenesis.

Multiple studies have been performed to characterize the RNA-binding specificity of FMRP ([@bib6]; [@bib16]; [@bib18]; [@bib53]; [@bib60]). Bioinformatic analysis of FMRP CLIP-seq datasets identified WGGA (W = T/A) as the top sequence motif ([@bib5]) which is found at six sites in the ZIKV 3′ UTR, each of them located in the dumbbell regions. Our mapping experiments, however, showed that the dumbbells are dispensable for FMRP binding to ZIKV 3′UTR, suggesting that these WGGA motifs do not mediate interaction with FMRP. Interestingly, using in vitro RNA selection Darnell et al. identified a highly structured target for the FMRP KH2 domain containing a pseudoknot ([@bib17]). To date, no FMRP target mRNA has been identified that contains this motif but it is notable that the ZIKV xrRNA1, which is required for FMRP binding in vitro, folds into a complex structure containing several tertiary interactions ([@bib2]). We speculate that the artificial RNA identified by Darnell and colleagues shares similar three-dimensional structural features with the sfRNA which allow it to bind FMRP with high affinity.

FMRP inhibited infection of multiple ZIKV strains but did not restrict the related flavivirus, DENV, even though we previously identified FMRP as a DENV RNA-binding protein by RNA affinity chromatography ([@bib68]), suggesting that FMRP acts as an intrinsic restriction factor for ZIKV. It is not clear why DENV infection is immune to FMRP. It is possible that DENV eludes physical interaction with FMRP in infected cells or that ribosomes translating DENV RNA do not effectively recruit FMRP, which is thought to be a prerequisite for translational repression ([@bib14]; [@bib9]). Notably, FMRP was recently described as a proviral host factor for influenza A virus that promotes assembly of viral RNPs, and FXR proteins were shown to redundantly promote replication of specific alphaviruses ([@bib76]; [@bib44]). Hirano et al. showed interaction of FMRP with the genomic RNA of Tick-Borne Encephalitis Virus (TBEV), accumulation of FMRP at sites of local TBEV replication, and that FMRP depletion reduces TBEV infection ([@bib42]; [@bib57]). Thus, FMRP can play a positive, negative or no role in infection, depending on viral species.

Mechanistically, we determined that FMRP inhibits ZIKV translation. FMRP is widely expressed and has been characterized to repress translation of specific neuronal mRNAs but the precise mechanism is unknown. Chen et al. demonstrated that drosophila FMRP (dFMRP) can bind directly to the ribosome in the absence of mRNA ([@bib14]). The authors proposed that FMRP docks on the 80S ribosome using KH1/2 domains and simultaneously binds to mRNA via its RGG motif. The binding location of dFMRP on the ribosome suggests that it occludes recruitment of elongation factors and tRNA, leading the ribosome reversibly stall as observed by Darnell et al. ([@bib18]). Based on this proposed mechanism, we speculate that FMRP binds the ZIKV genome within the viral open reading frame and causes elongating ribosomes to stall, leading to a deficiency in viral protein synthesis. Alternatively, it is possible that FMRP interaction with the 3′ UTR of the viral genome could lead to impaired translation. Finally, changes in the expression of FMRP targets may indirectly contribute to enhanced ZIKV infection upon FMRP knockdown. For example, the increase in FXR2 subsequent to FMRP depletion could positively impact ZIKV infection ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}).

We found that the recently developed ZIKV vaccine strain, Δ10 ZIKV, is compromised for sfRNA production and is replication-deficient in HeLa cells ([@bib66]; [@bib67]). Interestingly, infection with Δ10 ZIKV, but not WT ZIKV, caused relocalization of FXR2 to cytoplasmic granular structures reminiscent of stress granules (SG), suggesting that sfRNA may prevent SG formation. This is consistent with previous reports that show very low SG formation in flavivirus infected cells ([@bib8]; [@bib27]; [@bib63]). Importantly, Δ10 ZIKV infection was disproportionately increased by FMRP depletion compared to WT ZIKV, suggesting that one function of ZIKV sfRNA is to antagonize FMRP. In support of this, our RNA-IP experiments showed that FMRP preferentially co-IPs sfRNA compared to viral genomes. This may be partly explained by stoichiometry of sfRNA to genomes which reaches nearly 4 to 1 at the height of infection, depending on ZIKV strain. It is also possible that sfRNA structure differs from the corresponding region present in the viral genome and this dictates preferential FMRP interaction. We speculate that ZIKV sfRNA works as a 'sink' to saturate FMRP and prevent its repressive interactions with both viral RNA and cellular target mRNAs. This is reminiscent of recently described roles for the DENV sfRNA as a molecular sink for proteins involved in interferon responses (G3BP1, G3BP2, CAPRIN1, TRIM25) ([@bib8]; [@bib51]).

Besides interferon responses, there are intrinsic restriction factors that recognize viral components and block replication ([@bib72]). For flaviviruses, a few intrinsic anti-viral factors have been described: YTHDF1-3 proteins that bind methylated RNA and regulate stability, were reported to interact with ZIKV RNA and inhibit infection ([@bib50]); YB-1 and QKI bind to the DENV 3′ UTR and repress DENV RNA translation ([@bib49]; [@bib59]); similarly, FBP1 blocks translation of JEV through interacting with untranslated regions of JEV RNA ([@bib15]). The association of these antiviral factors with the viral genome and their functional consequences have only been observed in cell culture and it remains to be seen whether or not these will be validated in vivo. Furthermore, there are no reports that the intrinsic anti-viral function of these proteins is counteracted by flaviviral factors. In this work we describe that FMRP is an intrinsic, direct-acting ZIKV restriction factor that interacts with ZIKV RNA and is counteracted by the sfRNA as it accumulates during infection.

We provide evidence for de-repression of endogenous FMRP target mRNAs in the context of ZIKV infection of cultured cells and mouse testes. Specifically, we observed that the FMRP targets, *FXR2*, *TLN1*, *BRD4*, and *PNPLA6* were elevated at the protein level as a consequence of ZIKV infection. Moreover, infection with Δ10 ZIKV, which produces less sfRNA than WT virus, resulted in weaker or no effects on FMRP targets compared with WT ZIKV. We further observed that introduction of synthetic sfRNA into cells leads to upregulation of two FMRP targets: FXR2 and BRD4. These results provide functional evidence indicating that the ZIKV sfRNA interferes with the activity of FMRP, although sfRNA-independent mechanism(s) for modulation of FMRP targets by ZIKV may also be at play.

Our observations have implications for ZIKV pathogenesis in tissues with high expression of FMRP: brain, placenta and testes ([@bib41]). Given the well-established role for FMRP in promoting neurodevelopment, it is tempting to speculate that certain aspects of ZIKV neuropathogenesis may be explained by sfRNA-mediated FMRP inhibition, leading to inappropriate expression of FMRP target mRNAs. Development of congenital Zika syndrome is likely multifactorial and symptoms such as microcephaly, which is only one disease manifestation ([@bib3]), are unlikely to be the consequence of FMRP inhibition. Nevertheless, our findings warrant further research into how ZIKV interactions with FMRP might contribute to disease outcome.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\      Designation                    Source or reference   Identifiers                                                           Additional information
  (species) or\                                                                                                                                 
  resource                                                                                                                                      
  ------------------ ------------------------------ --------------------- --------------------------------------------------------------------- ------------------------
  Genetic reagent\   A129 IFNAR\                    UTMB, Galveston, TX   MGI:5652612                                                           [@bib61]\
  (*Mus musculus)*   Knock out mouse                                                                                                            PMID 27022155

  Antibody           4G2 antibody;\                 D1-4G2-4-15\          RRID for Hybridome\                                                   [@bib39]\
                     anti-Flavivirus\               Hybridome cell line   cell line: [CVCL_J890](https://scicrunch.org/resolver/CVCL_J890)      PMID 6285749
                     envelope\                                                                                                                  
                     (Mouse monoclonal)                                                                                                         

  Antibody           Anti-FMRP\                     Abcam                 Abcam Cat\# ab17722,\                                                 (1:1000)
                     (Rabbit polyclonal)                                  RRID:[AB_2278530](https://scicrunch.org/resolver/AB_2278530)          

  Antibody           Anti-FXR1\                     Cell Signaling\       Cat\#12295S                                                           (1:1000)
                     (Rabbit monoclonal)            Technology                                                                                  

  Antibody           Anti-FXR2\                     Cell Signaling\       Cell Signaling\                                                       (1:1000)
                     (Rabbit monoclonal)            Technology            Technology Cat\# 7098S,\                                              
                                                                          RRID:[AB_10891808](https://scicrunch.org/resolver/AB_10891808)        

  Antibody           Anti-G3BP1\                    Bethyl                Bethyl Cat\# A302-033A,\                                              (1:1000)
                     (Rabbit polyclonal)                                  RRID:[AB_1576539](https://scicrunch.org/resolver/AB_1576539)          

  Antibody           Rabbit\                        Homemade              Wagner and\                                                           (1:4000)
                     anti-PTB (Rabbit polyclonal)                         Garcia-Blanco, 2002.\                                                 
                                                                          PMID 12419237                                                         

  Antibody           Anti-ZIKV\                     Genetex               GTX133321                                                             (1:1000)
                     NS4B (Rabbit polyclonal)                                                                                                   

  Antibody           Anti-ZIKV\                     Genetex               GeneTex Cat\#\                                                        (1:1000)
                     NS2B (polyclonal)                                    GTX133308,\                                                           
                                                                          RRID:[AB_2715494](https://scicrunch.org/resolver/AB_2715494)          

  Antibody           Anti-BRD4\                     Cell Signaling\       Cell Signaling\                                                       (1:1000)
                     (Rabbit monoclonal)            Technology            Technology Cat\#\                                                     
                                                                          13440, RRID:[AB_2687578](https://scicrunch.org/resolver/AB_2687578)   

  Antibody           Anti-GAPDH\                    Abcam                 Abcam\                                                                (1:4000)
                     (Rabbit polyclonal)                                  Cat\# ab9485,\                                                        
                                                                          RRID:[AB_307275](https://scicrunch.org/resolver/AB_307275)            

  Antibody           Anti-TLN1\                     Santa Cruz\           Santa Cruz\                                                           (1:300)
                     (Mouse monoclonal)             Biotechnology         Biotechnology\                                                        
                                                                          Cat\# sc-365875,\                                                     
                                                                          RRID:[AB_10842054](https://scicrunch.org/resolver/AB_10842054)        

  Antibody           Anti-PNPLA6\                   Santa Cruz\           Santa Cruz\                                                           (1:1000)
                     (Mouse monoclonal)             Biotechnology         Biotechnology\                                                        
                                                                          Cat\# sc-271049,\                                                     
                                                                          RRID:[AB_10610321](https://scicrunch.org/resolver/AB_10610321)        

  Antibody           Anti-DDX6\                     Cell Signaling\       Cell Signaling\                                                       (1:1000)
                     (Rabbit polyclonal)            Technology            Technology\                                                           
                                                                          Cat\# 9407S,\                                                         
                                                                          RRID:[AB_10556959](https://scicrunch.org/resolver/AB_10556959)        

  Sequence-based\    siFMR1_10                      Qiagen                SI04916436                                                            TCCAAGGAACTTAGTAGGCAA
  reagent                                                                                                                                       

  Sequence-based\    siFMR1_4                       Qiagen                SI00031626                                                            TCCGTAATTCTTATTCCATAT
  reagent                                                                                                                                       

  Sequence-based\    siFMR1_3                       Qiagen                SI00031619                                                            CTCGTGAATGGAGTACCCTAA
  reagent                                                                                                                                       

  Sequence-based\    siFMR1_2                       Qiagen                SI00031612                                                            CTGTCAAACATTAGTACTTTA
  reagent                                                                                                                                       

  Sequence-based\    siFXR1_5                       Qiagen                SI03040429                                                            ACCGTCGTAGGCGGTCTCGTA
  reagent                                                                                                                                       

  Sequence-based\    siFXR1_3                       Qiagen                SI00072247                                                            GTGGTTCGAGTGAGAATTGAA
  reagent                                                                                                                                       

  Sequence-based\    siFXR1_2                       Qiagen                SI00072240                                                            CAGCTAAGAATGGAACGCCTA
  reagent                                                                                                                                       

  Sequence-based\    siFXR1_1                       Qiagen                SI00072233                                                            ATGGAATGACTGAATCTGATA
  reagent                                                                                                                                       

  Sequence-based\    siFXR2_8                       Qiagen                SI04347833                                                            TGGGTGATATGCATTTCCGAA
  reagent                                                                                                                                       

  Sequence-based\    siFXR2_7                       Qiagen                SI04332454                                                            CTGGAACGCACTAAACCCTCA
  reagent                                                                                                                                       

  Sequence-based\    siFXR2_6                       Qiagen                SI04316445                                                            AAACGTCCATAAAGAGTTCAA
  reagent                                                                                                                                       

  Sequence-based\    siFXR2_5                       Qiagen                SI04284763                                                            TGGAGCGACTTCGGCCAGTTA
  reagent                                                                                                                                       

  Commercial\        Northern Max kit               Thermo Fisher\        Cat\#:AM1940                                                          
  assay or kit                                      Scientific                                                                                  

  Commercial\        HiScribe T7 High\              New England\          Cat\#: E2040S                                                         
  assay or kit       Yield RNA\                     Biolabs                                                                                     
                     Synthesis Kit                                                                                                              

  Chemical\          NITD008                        Other                 CAS number:\                                                          [@bib73]\
  compound, drug                                                          1044589-82-3;\                                                        PMID 19918064
                                                                          Pubchem\                                                              
                                                                          ID: 44633776                                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell culture, viral stocks and infection {#s4-1}
----------------------------------------

JEG3 (human choriocarcinoma), HeLa (human cervix adenocarcinoma) and Vero cells were maintained in DMEM (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS) and 1 × penicillin/streptomycin (pen-strep) (Thermo Fisher Scientific) in a humidified incubator at 37°C with 5% CO~2~. C6/36 cells (Aedes albopictus) were grown in RPMI medium (Thermo Fisher Scientific) supplemented with 10% FBS (GenDEPOT) and 1 × pen strep and incubated at 28°C with 5% CO~2~. Cells were tested for mycoplasma contamination every three months. HeLa and JEG3 cells were authenticated by STR analysis at the UTMB Molecular Genomics Core. Dakar 41525 (ZIKV-Dakar), Cambodia FSS13025 (ZIKV-Cambodia) and PRVABC59 (ZIKV-Puerto Rico) strains were kindly provided by Scott Weaver (UTMB) and Nikos Vasilakis (UTMB) and propagated in C6/36 cells. DENV-2-NGC (New Guinea C strain) was propagated as previously described ([@bib65]). Nano-luciferase reporter ZIKV was engineered following the same strategy reported in Xie et al. ([@bib71]). Δ10 ZIKV and its WT version (ZIKV-Cambodia) were derived from infectious clones and propagated in Vero cells as described in ([@bib67]). Viral infections were performed in DMEM supplemented with 1% FBS. After 1 hr of incubation, media was replaced with complete DMEM media. MOIs and post-infection times are specified in the figures.

Virus titration {#s4-2}
---------------

ZIKV stocks and supernatants from [Figure 3](#fig3){ref-type="fig"} were analyzed by plaque assay in Vero cells ([@bib1]). Titers of DENV-2 stock, Δ10 ZIKV and WT ZIKV from infectious clones were performed in Vero cells using foci-forming assay as previously described ([@bib67]; [@bib65]).

Antibodies {#s4-3}
----------

The following antibodies were used for IP, western blotting and/or immunofluorescence analysis: anti-envelope protein 4G2 [@bib39], rabbit IgG (2729S, Cell Signaling Technologies), anti-FMRP (ab17722, ABCAM, Cambridge, UK), anti-FXR1 (12295S, Cell Signaling Technologies), anti-FXR2 (7098S, Cell Signaling Technologies), anti-G3BP1 (A302-033A, Bethyl Laboratories), rabbit anti-DDX6 (9407S, Cell Signaling technologies), rabbit anti-PTB (homemade), rabbit anti-ZIKV NS4B (GTX133321, Genetex), anti-ZIKV NS2B (GTX133308, Genetex), anti-BRD4 (13440, Cell Signaling Technologies), anti-GAPDH (ab9485, ABCAM), anti-TLN1 (SC-365875, Santa Cruz Biotechnology), anti-PNPLA6 (SC-271049, Santa Cruz Biotechnology).

RNA affinity chromatography and mass spectrometry {#s4-4}
-------------------------------------------------

Synthetic DNA fragments corresponding to the complete 3′ UTRs of African (strain MR766, accession number KX377335.1) and pandemic Asian-lineage ZIKV (PRVABC59 strain, KX377337.1) were obtained from IDT (Integrated DNA Technologies) and cloned into pcDNA3.1(+) plasmid containing tobramycin aptamer ([@bib49]). As a control RNA we used a sequence corresponding to the DENV NS2A sequence as previously reported ([@bib51]). PCR was used to generate DNA templates for T7 in vitro transcription using the MEGAscript T7 kit (Thermo Fisher Scientific). RNA affinity chromatography using JEG3 cell lysate was performed following the published protocol ([@bib69]). Eluted RBPs were identified by label-free mass spectrometry at the UTMB Mass Spectrometry Core. Samples were dissolved in 30 μl denaturation buffer (4% SDS and 100 mM DTT in 0.1M TEAB pH 8.5), heated at 65°C for 15 min, and loaded onto 30 kDa spin filters (Merck Millipore). The buffer was exchanged three times with UA solution (8 M UREA in 0.1 M TEAB pH 8.5) by centrifugation at 14,000 g. After removal of SDS, cysteine alkylation was accomplished through the addition of alkylation buffer (50 mM IAA, 8 M UREA in 0.1 M Tris-HCl pH 8.5) for 1 hr at room temperature in the dark. UA buffer was exchanged with TEAB buffer (40 mM TEAB pH 8.5). The proteins were digested with trypsin (enzyme-to-substrate ratio \[w/w\] of 1:100) and 5% ACN at 37°C overnight. Peptides were centrifuged through the size exclusion membrane and collected into a clean microcentrifuge tube, followed by a rinse with 80 μL of 0.2% formic acid. The combined peptide solution was then dried in a speed vac and resuspended in 2% acetonitrile, 0.1% formic acid, 97.9% water and placed in an autosampler vial for LC/MS analysis. Raw data files from the mass spectrometer were aligned by accurate mass and time in Progenesis QI for proteomics (version 2.0.5556.29015, Nonlinear Dynamics, a Waters Company). The top five spectra for each feature were exported as \*.mgf files and searched against a combined Uniprot-Human canonical database. Peptide identifications were imported into Progenesis QI, and all peptides with −10logP scores \< 30 (Mascot or confidence score) were removed. Conflict resolution was performed in order to remove lower scoring peptides when multiple peptides were assigned to a single feature. Protein quantification was calculated from normalized peptide abundances using a summed abundance of unique peptides. Unique peptide abundance was calculated by the area of the corresponding peaks in the ion chromatograms. Protein abundance from RBPs interacting with PRVABC59 and MR766 ZIKV 3′ UTRs were compared with control RNA to calculate ratios of enrichment (PRVABC59 3′ UTR/NS2A and MR766 3′ UTR/NS2A). Eight proteins that were identified by ≥2 unique peptides and were found ≥2 times in both the ZIKV sequences relative to the control RNA were considered high-confidence ZIKV 3′ UTR binding proteins RBPs with ratio \>2 were considered as enriched.

Immunoprecipitation {#s4-5}
-------------------

1.5 × 10^6^ HeLa cells were plated in 10 cm dishes. 24 hr later, cells were infected with ZIKV-Dakar, ZIKV-Cambodia and ZIKV-Puerto Rico at an MOI of 3 for 48 hr. Cells were washed three times with cold PBS, scraped and pelleted in 3 mL of PBS (5 min, 1500 rpm at 4°C). Cell pellets were resuspended in an equal volume of RIPA buffer (Cell Signaling Technologies) with protease inhibitors (Roche). All steps of the IP were performed at 4°C. For each IP 100 µL of protein A/G PLUS-Agarose (Santa Cruz Biotechnology) was washed with 1 ml NT2 buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM MgCl~2~ and 0.05% IGEPAL) and blocked for 30 min in NT2 buffer with 0.5 mg/mL BSA. Beads were washed three times with NT2 buffer and incubated with either 10 µg of rabbit anti-FMRP, anti-PTB or rabbit IgG in a total volume of 600 µL of NT2 buffer for 2 hr with head to tail rotation. After coupling antibodies, beads were washed three times with NT2 buffer. One mg of protein from clarified lysate was diluted in NT2 buffer in a total volume of 600 µL and added either to IgG or FMRP beads and incubated with rotation for 1 hr. After incubation, beads were pelleted, washed four times with NT2 buffer and resuspended in 115 µL of NT2. 15 µL of beads were used for WB and 100 µL for RNA isolation using Trizol. Equal volumes of RNA (5 µL) from IP reactions were processed for Northern blotting.

Northern Blot {#s4-6}
-------------

The NorthernMax kit (Thermo Fisher Scientific) was used following the manufacturer´s instructions. RNA was mixed with 3 volumes of formaldehyde loading dye, then incubated 15 min at 65°C and 2 min on ice. Electrophoresis was performed in denaturing 1% agarose gels at 95 V. After electrophoresis, the gel was incubated in alkaline buffer (0.01N NaOH, 3M NaCl) for 20 min and transferred to a Biodyne B nylon membrane (Thermo Fisher Scientific) by downward transfer. RNA was crosslinked to the membrane using the UV stratalinker 2400 auto-crosslink program. The membrane was pre-hybridized for 30 min with ULTRAhyb-oligo Buffer (Thermo Fisher Scientific) at 42°C and hybridized overnight at 42°C with a Biotin-labeled DNA probe to detect ZIKV 3′ UTR (10453--10739 nt). The DNA probe was generated by PCR using 60% of unmodified dTTP and 40% biotin-16-dUTP (Roche). Specific primers (forward: 5′ AGGAGAAGCTGGGAAACCAAGC 3′; reverse: 5′ GATAATACGACTCACTATAGGAAACTCATGGAGTCTCTGGTC 3′) and apt-MR766 3′ UTR plasmid (template) were used to generate the biotin-labeled probe. For [Figure 7](#fig7){ref-type="fig"} northern blots, RNA was mixed with 2X TBE-Urea loading sample and resolved in 6% acrylamide TBE, 8M Urea gels and transferred to nylon membrane in 0.5% TBE for 3 hr using the XCell II Blot module (Thermo Fisher Scientific). The membrane was crosslinked and hybridized with a DNA probe to detect the ZIKV 3′ UTR DB and SLIII (10528--10807 nt). This probe was generated as above using specific primers (forward: 5′ GATAATACGACTCACTATAGGGCCCCTCAGAGGACACTGAGTCAAAAAA 3′; reverse: 5′ AGAAACCATGGATTTCCCCACACCGGCCGCCGCT 3′). After hybridization, the membranes were washed and incubated for 1 hr at room temperature with IRDYE 800CW streptavidin (LI-COR Biosciences) in Odyssey Blocking Buffer (LI-COR Biosciences) with 1% of SDS. After three washes with TBS containing 0.1% tween, the membrane was scanned using a LI-COR Odyssey instrument. Densitometry was performed using Image Studio Lite Ver 5.0 software.

siRNA transfection {#s4-7}
------------------

Protein knockdown was performed using individual siRNAs (Qiagen) or a pool of siRNAs. 3 × 10^4^ HeLa cells were plated in a 24 well plate. The next day cells were transfected with AllStars Negative Control siRNA (Qiagen), individual siRNAs, or the pool using 30 nM of siRNA and 1.5 µL of RNAiMAX (Thermo Fisher Scientific) diluted in 50 µL of Opti-MEM media (Thermo Fisher Scientific). After 4 hr, transfection media was replaced by fresh media and cells were incubated for 48 hr. HeLa cells were infected as noted in the figure legends.

Western blotting {#s4-8}
----------------

Cells were lysed in RIPA buffer (Cell Signaling Technologies) with 1X protease inhibitor. 10 µg of protein samples were resolved under denaturing conditions on 4--12% acrylamide gels (Thermo Fisher Scientific). ZIKV NS4B, and NS2B, BRD4, TLN1, PNPLA6, Actin and GAPDH were detected using primary antibodies mentioned above. Goat anti-mouse IgG and goat anti-rabbit IgG coupled with IRDye 800 or 680 (LI-COR Biosciences) were used as secondary antibodies. Blots were developed in the LI-COR Odissey luminescence system and protein expression was quantified by densitometry with the Image Studio Lite Ver 5.0 software.

Flow cytometry {#s4-9}
--------------

Cells were harvested and fixed with 1% formaldehyde, permeabilized and blocked for 20 min (1X PBS, 0.1% tween 20, 5% FBS), incubated for 1 hr at room temperature with mouse 4G2 antibody and then 1 hr with goat anti-mouse IgG Alexa fluor 647 (Thermo Fisher Scientific) to detect ZIKV envelope protein (E protein). E protein fluorescence was measured with the Guava easyCyte system (Millipore) using the red laser (642 nm) for [Figures 3](#fig3){ref-type="fig"} and [5](#fig5){ref-type="fig"} and [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"}--[3](#fig3s3){ref-type="fig"}. Double staining was performed for [Figure 6](#fig6){ref-type="fig"} to detect E protein and cellular FXR2 protein. E protein was detected using mouse 4G2 antibody and goat anti-mouse IgG Alexa fluor 488. FXR2 protein was stained using rabbit anti-FXR2 and goat anti-rabbit IgG Alexa fluor 647. Sample analysis, scatter plots of infected cells, mean fluorescence intensities and histograms were performed in FlowJo V10 software.

Immunofluorescence staining {#s4-10}
---------------------------

To determine percentage of infection, 3 × 10^4^ HeLa cells per well were plated in 24-well plates. 24 hr later, cells were transfected with control siRNA or FMR1 siRNA (pool). After 48 hr of knockdown, cells were infected with ZIKV-Dakar for 48 hr, fixed with 1% paraformaldehyde, permeabilized and blocked for 20 min (1 × PBS, 0.1% tween 20, 1% FBS), and incubated for 1 hr at room temperature with mouse 4G2 mouse (E protein) and 1 hr with Goat anti-mouse IgG Alexa fluor 647. Nuclei were counterstained with Hoechst 33342 (Sigma-Aldrich). Image acquisition and infection rates were calculated using a high-content imaging microscope (Opera Phenix, Perkin Elmer). To visualize the accumulation of FXR2 protein in infected cells, glass slides with non-infected or ZIKV infected cells (WT or Δ10 ZIKV) for 24 hr were fixed, permeabilized and blocked as described above. Viral protein was detected using 4G2 antibody and goat anti-mouse IgG Alexa fluor 488. FXR2 protein was stained using rabbit anti-FXR2 and goat anti-rabbit IgG Alexa fluor 647. Nuclei were counterstained with Hoechst 33342 (Sigma-Aldrich) and images were acquired using an Olympus fluorescence microscope.

Evaluation of viral translation using NanoLuc ZIKV reporter {#s4-11}
-----------------------------------------------------------

5 × 10^4^ HeLa cells were plated in 24-well plates. Next day, cells were transfected with control siRNA or FMR1_2 siRNA. After 46 hr of knockdown, cells were treated with 0.05% DMSO or 20 µM NITD008 for 2 hr before infection with the ZIKV reporter at an MOI of 3. NITD008 or DMSO were retained in media during the infection. After 1 hr of incubation, inoculum was retired and replaced with fresh media containing DMSO or NITD008. 2.5 hr later, cells were washed five times with 1 × PBS and lysed with *Renilla* lysis buffer (Promega). Additionally, cycloheximide (CHX) treatment (200 µM) was used as a background control in absence or presence of NITD008. For this condition, cells were pretreated with CHX (in absence or presence of NITD008) for 2 hr before ZIKV reporter infection and CHX was retained during infection until cell lysis. Luciferase assays were performed using the High-Affinity NanoBit evaluation system (Promega) and the Enspire plate reader (Perkin Elmer).

Viral RNA quantitation {#s4-12}
----------------------

Viral genome and GAPDH RNA were quantified by RT-qPCR. Cell-associated RNA from HeLa was extracted by the Trizol method (Thermo Fisher Scientific) and reverse transcribed using the MultiScribe Reverse transcriptase protocol (Thermo Fisher Scientific). qPCR was performed with SYBR mix on a StepOne plus instrument (Thermo Fisher Scientific). The ΔΔCT method was used to calculate relative expression levels of viral genome. Primers used for ZIKV ORF (nucleotides 4541 to 4631 of ZIKV-Cambodia: forward 5′ CTGTGGCATGAACCCAATAG 3′; reverse 5′ ATCCCATAGAGCACCACTCC 3′). Primers used for human GAPDH (forward 5′ AGCCACATCGCTCAGACAC 3′; reverse 5′ GCCCAATACGACCAAATCC 3′). To evaluate viral genome in mice, RNA from testes lysates were obtained by diluting 15 µL of cell lysate in 85 µL of NT2 buffer and 300 µL of Trizol LS. RNA transcription and qPCR were performed as mentioned above using primers for ZIKV ORF and mouse GAPDH (forward 5′ AAGGTCATCCCAGAGCTGAA 3′; reverse 5′ AAGGTCATCCCAGAGCTGAA 3′).

Evaluation of FMRP-viral genome interaction and FMRP targets in mice {#s4-13}
--------------------------------------------------------------------

All animal studies were done in accordance with IACUC protocols as per UTMB policy. A129 mice were obtained from colonies maintained under specific pathogen-free conditions. Male 8--9 week-old A129 mice were infected with 1 × 10^5^ FFU of WT (n = 4) or Δ10 ZIKV (n = 4) mutant viruses through the intraperitoneal route. PBS was given to the mock-infected mice through the same route (n = 3). At 6 days post-infection mice were euthanized, and testes were removed immediately as previously described ([@bib36]). Testes were flash-frozen in dry ice and stored at −80°C. Tissue was homogenized and lysed with a tissue grinder (OmniTHQ) in 500 µL of polysome lysis buffer (10 mM HEPES pH 7.0, 100 mM KCl, 25 mM EDTA, 5 mM MgCl~2~,1 mM DTT, 0.5% NP-40). RNasin 1:1000 dilution (Promega) and protease inhibitor (Roche) were freshly added to samples. Samples were rotated for 10 min at 4°C to induce lysis and then flash-frozen on dry ice. Samples were thawed and nuclei were pelleted at 3000 x g for 10 min. 10 µg of protein samples from tissue lysates were fractionated in a 4--12% acrylamide gel (Thermo Fisher Scientific), transferred to a nitrocellulose membrane and blotted for FXR2, PNPLA6 and GAPDH with antibodies mentioned above. For RIP, testis lysate obtained from a mouse infected with WT ZIKV (ZIKV-Cambodia) was pre-cleared by adding 50 µL of protein A/G PLUS-Agarose (Santa Cruz Biotechnology) and rotating for 30 min at 4°C. 50 µL of beads were blocked in 600 µL of NT2 buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM MgCl~2~, 1 mM DTT, 0.05% NP-40) with 0.5 mg/mL BSA (Thermo Fisher Scientific) and 0.5 mg/mL yeast tRNA (Sigma-Aldrich). After blocking, beads were washed and incubated overnight at 4°C with 10 µg of either FMRP or Rabbit IgG antibodies. Antibody-bound beads were washed four times with ice-cold NT2 buffer. For the IP, 2 mg of pre-cleared protein was added to the antibody-bound beads. Final volume was adjusted to 600 µL with NT2 buffer containing RNase and protease inhibitors and incubated for 1.5 hr at 4°C. After incubation, beads were washed four times with NT2 buffer and processed for WB and RNA isolation as in the RIP for HeLa cells. qPCR was performed using ZIKV ORF primers described above and specific primers that amplify ZIKV 3′ UTR (nucleotides 10623 to 10722 of ZIKV-Cambodia: forward 5′ CCTGAACTGGAGATCAGCTGTG 3′; reverse 5′ GGTCTTTCCCAGCGTCAATA 3′).

RNA electroporation {#s4-14}
-------------------

5′ triphosphate RNAs were generated as described above using the HiScribe T7 High Yield RNA Synthesis Kit (New England Biolabs) and specific primers for sfRNA (forward: 5′ GATAATACGACTCACTATAGGGT GTTGTCAGGCCTGCTAGTCAGCCACAGC 3′; reverse: 5′ AGAAACCATGGATTTCCCCACACCGGCCGCCGCT 3′) and the DBSLIII mutant (forward: 5′ GATAATACGACTCACTATAGGGCCCCTCAGAGGACACTGAGTCAAAAAA 3′). 5′ monophosphate RNAs were by generated by synthesis of capped RNAs followed by treatment with Tobacco Acid Pyrophosphatase (Thermo Fisher Scientific). 5′ tri- and monophosphate RNAs were treated with the Turbo DNAse I (Thermo Fisher Scientific). RNAs were purified using Trizol LS and Direct Zol RNA MiniPrep (Zymo Research) for RNA clean up. 36 pmol of DBSLIII or sfRNA were electroporated into 2 × 10^6^ HeLa cells in 250 µL of Ingenio electroporation solution (Mirus) using the Gene Pulser X cell Electroporation System (Bio-Rad Laboratories) following manufacturer´s instructions. 48 hr post electroporation, cells were analyzed for expression of FXR2 and BRD4 and transfection efficiency by NB as described above.

Experimental design and statistical analysis {#s4-15}
--------------------------------------------

The independent experiments were performed with three biological replicates except for [Figure 2A and B](#fig2){ref-type="fig"}. For [Figure 2C](#fig2){ref-type="fig"} two infected mice, each with three technical replicates, were processed separately. Differences between treatments and control groups were evaluated using the SigmaPlot/Stat package 11. In all cases, parametric or nonparametric tests and the appropriate post-hoc test were applied. If data met with assumptions of normality (Shapiro-Wilk test) and equal variance test, a *t*-test (parametric) was conducted. Data that did not meet with either normality test or equal variance test were analyzed using Mann-Whitney U test.
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Decision letter

Simon

Viviana

Reviewing Editor

Icahn School of Medicine at Mount Sinai

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Fragile X mental retardation protein is Zika virus restriction factor that is antagonized by subgenomic flaviviral RNA\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Wenhui Li as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The translational repressor protein FMRP has been previously implicated as a host factor that modulates viral infectivity, for example as a Dengue virus (DENV) RNA binding protein (RBP), an influenza A RNP assembly factor and a positive host factor for Tick-Borne Encephalitis Virus infection. Additionally, the FMRP-related FXR proteins enhance replication of some alphaviruses. In this manuscript, Soto-Acosta and coworkers add to this list by using RNA affinity chromatography and MS to identify a number of host proteins that bind to the Zika virus 3\'UTR. Among these proteins FMRP, and related proteins FXR1 and FXR2, were selected for further studies. These proteins bind a specific RNA structure of the viral 3\'UTR known as xrRNA1, which is present in the viral genome and in viral sfRNAs. FMRP, a cellular RNA-binding protein (RBP) that binds to the 3\'UTR of Zika virus, inhibits virus production by interfering with viral translation. FMRP binds a specific 3\' UTR region (xrRNA1) of ZIKV subgenomic RNA (sfRNA), which accumulates during ZIKV infection and inhibits FMRP inhibitory activity. Using siRNA-mediated FMRP depletion, they provide evidence that FMRP loss increases ZIKV translation/infection and also stimulates sfRNA-deficient ZIKV10-del. ZIKV also upregulates FMRP translational targets in both Hela cells and mouse testes.

Studies on ZIKV continue to be of biomedical concern due to ZIKV-associated congenital microcephaly and inflammatory peripheral neuropathy. In this context, the findings reported in this study are important since they add to our understanding by dissecting the interaction of FMRP/FXR proteins with sfRNA. Overall, the described experiments are well-controlled, the manuscript is well-written and the finding that FMRP acts as a restriction factor for ZIKV infection is novel and of high interest. The reviewers felt, however, that key experiments were missing to fully support the conclusions. Especially, the conclusion that sfRNA strongly antagonizes FMRP activity is less well supported because it is mainly based on an attenuated ZIKV strain with distinct replication kinetics.

Essential revisions:

1\) Further testing of the specificity of the FMRP-sfRNA interaction is needed.

1a) The Δ10 mutation produces less sfRNAs but its attenuation can be due to any number of reasons. For example, the 3\'UTR is crucial for recruiting pro-viral RBPs that aid in translation and replication; the Δ10 mutation can disrupt this independently of sfRNAs. Thus, the observation that the attenuated virus is rescued to a higher extent upon FMRP depletion could be due to other non sfRNA related mechanism. More direct evidence is required to support the claim that sfRNA antagonizes FMRP activity. Is it possible to transfect sfRNA (and non-FMRP binding mutant sfRNA) in the cell and show effects on FMRP activity outside of the context of infection?

1b) Figure 5. shows that Δ10 ZIKV is disproportionately enhanced by FMRP KD. While WT virus was enhanced 3.5 fold, the infection rate of the Δ10 ZIKV rose near 5 fold. However, in Figure 3C silencing of FMRP increases the infection rate of the WT about 6 fold. Are these experiments comparable?

1c) For Figure 2A and B, at least one RBP control antibody, and not just IgG, should be included in this RIP to confirm preferential interaction of FMRP with sfRNA over an unrelated RBP. For Figure 2C, FMRP is relatively abundant in testes with a high viral load but the FMRP-RIP signal is low (again an unrelated RBP RIP is an important control) -- how do the authors explain this result?

1d) Can the authors exclude that the enrichment for sfRNA is not due to RNA degradation during the IP?

1e) Although FXR2 is a FMRP translational target, FXR2 also binds sfRNA (Figure 1B). In Figure 6, WT ZIKV upregulates FXR2 expression, presumably through FMRP inhibition, so it is important to confirm that siFXR2 does not cause upregulation of the ZIKV NanoLuc reporter in Figure 4.

2\) The possibility that FXR2 is relocalizing to stress granules should be tested using a SG marker.

3\) Clarification of the mechanism of restriction. Based on the known function of FMRP, the authors focused on viral translation (subsection "FMRP represses ZIKV infection by blocking viral RNA translation", last paragraph) but it is unclear whether this protein acts directly on the viral RNA.

3a) Does the protein need to bind the 3\'UTR or the ORF for this activity? Does it work directly or indirectly? It is possible that the increase infection could be a consequence of alteration of the expression of FMRP targets. This issue should be considered and different possibilities should be at least discussed.

3b) In Figure 4, what are the kinetics of viral RNA replication in FMRP KD cells with the NanoLuc reporter system? This analysis can add useful mechanistic information.

10.7554/eLife.39023.029

Author response

> Essential revisions:
>
> 1\) Further testing of the specificity of the FMRP-sfRNA interaction is needed.
>
> 1a) The Δ10 mutation produces less sfRNAs but its attenuation can be due to any number of reasons. For example, the 3\'UTR is crucial for recruiting pro-viral RBPs that aid in translation and replication; the Δ10 mutation can disrupt this independently of sfRNAs. Thus, the observation that the attenuated virus is rescued to a higher extent upon FMRP depletion could be due to other non sfRNA related mechanism. More direct evidence is required to support the claim that sfRNA antagonizes FMRP activity. Is it possible to transfect sfRNA (and non-FMRP binding mutant sfRNA) in the cell and show effects on FMRP activity outside of the context of infection?

This is an excellent comment and we agree that demonstration of FMRP modulation by sfRNA out of the context of the infection would strengthen our conclusions. To address this we performed electroporation of sfRNA and a mutant version with deletion of xrRNA1 and xrRNA2, regions required for FMRP-sfRNA interaction. Levels of established targets of FMRP (FXR2 and BRD4) were analyzed by flow cytometry. These experiments show that introduction of sfRNA in uninfected cells leads to increased levels of FXR2 and BRD4, supporting a role for ZIKV sfRNA in FMRP inhibition. Data from these experiments are shown in new Figure 7.

> 1b) Figure 5. shows that Δ10 ZIKV is disproportionately enhanced by FMRP KD. While WT virus was enhanced 3.5 fold, the infection rate of the Δ10 ZIKV rose near 5 fold. However, in Figure 3C silencing of FMRP increases the infection rate of the WT about 6 fold. Are these experiments comparable?

We appreciate this request for clarification. The experiments referred to are not comparable: Figure 3C was performed with the WT Dakar strain and the experiments in Figure 5 used WT Cambodia strain derived from the previously reported infectious clone. A closer comparison could be performed with the Figure 3---figure supplement 1B where the increase in the WT Cambodia strain was 2.5-fold. We emphasize in the revised manuscript that different ZIKV strains exhibited somewhat different sensitivities to FMRP depletion.

> 1c) For Figure 2A and B, at least one RBP control antibody, and not just IgG, should be included in this RIP to confirm preferential interaction of FMRP with sfRNA over an unrelated RBP. For Figure 2C, FMRP is relatively abundant in testes with a high viral load but the FMRP-RIP signal is low (again an unrelated RBP RIP is an important control) -- how do the authors explain this result?

We agree that IP of an unrelated RBP would provide additional evidence for specificity of ZIKV-FMRP interaction. In response to this comment we performed additional RNA immunoprecipitation assays with the polypyrimidine tract-binding protein (PTB) along with northern blot analysis. This revealed that sfRNA strongly prefers interaction with FMRP compared to PTB. These results are included in new Figure 2C. Regarding the experiment with mouse testes shown in Figure 2C we speculate that efficiency of IP from this tissue was relatively inefficient compared to IP from cultured cells. Nevertheless, this experiment showed clear enrichment of ZIKV RNA with FMRP IP.

> 1d) Can the authors exclude that the enrichment for sfRNA is not due to RNA degradation during the IP?

The reviewers make a good point concerning the possibility of differential RNA decay during the RNA IP reaction. To address this, we analyzed ZIKV genomes and sfRNA in supernatants from RNA IP reactions by Northern blot side-by-side with input RNA. This showed that both viral genomes and sfRNA remain intact during the IP. These data are shown in new Figure 2C.

> 1e) Although FXR2 is a FMRP translational target, FXR2 also binds sfRNA (Figure 1B). In Figure 6, WT ZIKV upregulates FXR2 expression, presumably through FMRP inhibition, so it is important to confirm that siFXR2 does not cause upregulation of the ZIKV NanoLuc reporter in Figure 4.

We agree it is of interest to determine what effects FXR2 may have on ZIKV infection as well as FXR1. We performed knockdown of these proteins and observed contrasting effects: FXR2 knockdown decreased rate of ZIKV infection, making it unlikely to repress ZIKV translation, while FXR1 depletion slight enhanced infection. These observations are now shown in new Figure 3---figure supplement 2.

> 2\) The possibility that FXR2 is relocalizing to stress granules should be tested using a SG marker.

We made the interesting observation that FXR2 relocalizes to granular structures upon infection with the Δ10, but not WT, ZIKV. While it is possible these are stress granules, we respectfully submit that testing this hypothesis is beyond the scope of our study.

> 3\) Clarification of the mechanism of restriction. Based on the known function of FMRP, the authors focused on viral translation (subsection "FMRP represses ZIKV infection by blocking viral RNA translation", last paragraph) but it is unclear whether this protein acts directly on the viral RNA.
>
> 3a) Does the protein need to bind the 3\'UTR or the ORF for this activity? Does it work directly or indirectly? It is possible that the increase infection could be a consequence of alteration of the expression of FMRP targets. This issue should be considered and different possibilities should be at least discussed.

The reviewers raise an important point. Our combined data showing binding of FMRP to ZIKV RNA and correlated enhanced infection/translation due to FMRP knockdown strongly suggest that the effect of FMRP is direct. While this is the most parsimonious explanation, our data do not prove that this is the case and it is possible that alteration in expression of FMRP targets contributes to the effect on ZIKV infection. Likewise, our data do not inform on whether binding to the 3' UTR or ORF restricts virus translation. These possibilities are noted in the revised manuscript Discussion.

> 3b) In Figure 4, what are the kinetics of viral RNA replication in FMRP KD cells with the NanoLuc reporter system? This analysis can add useful mechanistic information.

The experiments in Figure 4 were performed at a short time point in the presence or absence of the NS5 inhibitor, NITD008, to account for a possible contribution of viral RNA synthesis to luciferase signals. We do not know the kinetics of RNA synthesis with this modified virus but we observed essentially no difference plus or minus NITD008 in the effects of FMRP knockdown on luciferase levels. This lack of difference is the critical point to note. We interpret these data as evidence supporting a role for FMRP in ZIKV translational repression.
